Pancreatic Cancer Research

ResearcherZhejiang Provincial People's HospitalActive in the last 2 years

Zheling Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3073-1811; OpenAlex author ID A5026501857. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2020: 3 papers · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 11

  1. A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment. Co-author DOI 10.1016/j.canlet.2025.217934↗
  2. Third-line treatment options in metastatic pancreatic cancer patients: a real-world study. Co-author DOI 10.3389/fonc.2023.1251258↗
  3. Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties. Co-author DOI 10.1016/j.biopha.2022.112713↗
  4. Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review. Co-author DOI 10.1097/cad.0000000000001232↗
  5. Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer? Co-author DOI 10.1097/cad.0000000000001235↗
  6. Conversion Therapy of Unresectable Pancreatic Cancer: A Retrospective Study of the Real World Co-author DOI 10.21203/rs.3.rs-674137/v1↗
  7. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment. Co-author DOI 10.3389/fimmu.2021.691605↗
  8. Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.771247↗
  9. Laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic outcomes and long-term survival. Last author DOI 10.1007/s00464-019-06968-8↗
  10. A Peptide-Based Neoantigen Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment Co-author DOI 10.21203/rs.3.rs-130888/v1↗
  11. Conversion Therapy for Advanced Pancreatic Cancer: The Case Series and Literature Review. Co-author DOI 10.3389/fphar.2020.579239↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Liu Yang · 6 shared papers, 2021–2025 · strength 1.13
  2. Mingxing Wang · 4 shared papers, 2020–2022 · strength 0.70
  3. Peng-Fei Zhu · 3 shared papers, 2021–2023 · strength 0.60
  4. Jiahong Jiang · 4 shared papers, 2020–2021 · strength 0.45
  5. Yunyun Xu · 3 shared papers, 2020–2021 · strength 0.32
  6. Dongsheng Huang · 2 shared papers, 2020–2021 · strength 0.24
  7. Hongrui Lu · 1 shared paper, 2023 · strength 0.24
  8. Yunhua Liu · 1 shared paper, 2025 · strength 0.23
  9. Yang Liu · 1 shared paper, 2022 · strength 0.17
  10. Ke Chen · 1 shared paper, 2022 · strength 0.15
  11. Qingyong Ma · 1 shared paper, 2022 · strength 0.15
  12. Zheng Wu · 1 shared paper, 2022 · strength 0.15
  13. Ying Xiao · 1 shared paper, 2022 · strength 0.15
  14. Tao Qin · 1 shared paper, 2022 · strength 0.15
  15. Weikun Qian · 1 shared paper, 2022 · strength 0.15
  16. Erxi Wu · 1 shared paper, 2022 · strength 0.15
  17. Jiguang Ma · 1 shared paper, 2022 · strength 0.15
  18. Zheng Wang · 1 shared paper, 2022 · strength 0.15
  19. Ke Chen · 1 shared paper, 2020 · strength 0.11
  20. Yuanyu Wang · 1 shared paper, 2020 · strength 0.11
  21. Nan Niu · 1 shared paper, 2020 · strength 0.11
  22. Yucheng Zhou · 1 shared paper, 2020 · strength 0.11
  23. Chao Lu · 1 shared paper, 2020 · strength 0.11
  24. Weiwei Jin · 1 shared paper, 2020 · strength 0.11
  25. Yiping Mou · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.